Diabetes Connections | Type 1 Diabetes Podcast Por Stacey Simms arte de portada

Diabetes Connections | Type 1 Diabetes

Diabetes Connections | Type 1 Diabetes

De: Stacey Simms
Escúchala gratis

The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.Stacey Simms Media 2015-2026 Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • In the News... Insulin Act, weekly basal approved, weight loss pill okayed, gene therapy for T1D and more!

    In the News... Insulin Act, weekly basal approved, weight loss pill okayed, gene therapy for T1D and more!
    Apr 7 2026

    It's In the News, a look at the top headlines and stories in the diabetes community.

    This week's top stories: Senate Insulin Act moves forward, FDA approveds Awiqli for type 2 and and second oral GLP-1 pill, lots of updates on stem cell and gene therapy for type 1, updates from Beta Bionics, veterans group and Dexcom team up, and Omnipod features on Scrubs. Much more in the episode!

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Stacey mentioned these two groups:

    Grownup T1Ds

    T1D to 100


    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Más Menos
    14 m
  • Grownup T1Ds: The Missing Support for Adults Living with Diabetes

    Grownup T1Ds: The Missing Support for Adults Living with Diabetes
    Mar 31 2026

    There's a reason we don't call it juvenile diabetes anymore. We all know you grow up and T1D doesn't go anywhere, and that you can be diagnosed at any age. But it often feels like adults are forgotten.

    I hope that's not the case here—but I hear it all the time in the broader community.

    Kelly Dawes is working to change that. She's started GrownUp T1Ds, a community built specifically for adults who've been living with type 1 for years and are finally finding connection, understanding, and support in a way they may never have had before.

    This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.

    More about Grownup T1Ds here

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Más Menos
    37 m
  • In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more

    In the News... the "Next Ozempic" moves forward, diabetes and dementia link, tech updates & approvals, ATTD news and more
    Mar 24 2026
    It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com transcript with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it. https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice. The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests XX Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments. https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX ...
    Más Menos
    11 m
Todavía no hay opiniones